Shkreli Had No Trouble Courting Investors, Financier Says at Trial
His pitch, she said, was “you can make a lot of money on orphan drugs, because the price per patient is quite high.”
Ms. Hassan testified that Mr. Shkreli told her that Mr. Saunders
and other wealthy people were backing Retrophin, and Ms. Hassan invested another $150,000 of DynaGrow’s $20 million into the company.
A colleague of her father’s had told her that Mr. Shkreli was on the upswing, and his investing returns had made the colleague “ecstatic.”
Ms. Hassan invested $300,000 with Mr. Shkreli’s fund, wanting “to learn from him,” she testified on Thursday.
Brent Saunders, who introduced Ms. Hassan and Mr. Shkreli, was chief executive of Bausch & Lomb
and is now the chief executive of the pharmaceutical giant Allergan.
Mr. Shkreli had asked her to arrange a meeting with her father, whom Mr. Shkreli’s lawyer, Benjamin Brafman, described
during cross-examination as “a legend in the pharmaceutical industry.” Ms. Hassan did so; nothing came of it.
About a month after Ms. Hassan invested, Mr. Shkreli emailed her to say that her investment had increased to $324,600.